The best explanation is that diffuse astrocytic and oligodendroglial tumors are classified by the presence of isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation in the 2016 World Health Organization (WHO) classification of central nervous system (CNS) tumors for the impact of specific gene mutations on the progression and patient outcome of glioma [64]. This evidence concerns the gene IDH1 and central nervous system cancer.